{"id":48637,"date":"2025-11-19T20:27:57","date_gmt":"2025-11-19T12:27:57","guid":{"rendered":"https:\/\/flcube.com\/?p=48637"},"modified":"2025-11-19T20:27:58","modified_gmt":"2025-11-19T12:27:58","slug":"roches-lunsumio-sc-wins-eu-conditional-approval-for-follicular-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48637","title":{"rendered":"Roche&#8217;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma"},"content":{"rendered":"\n<p><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted <strong>conditional marketing authorization<\/strong> for <strong>Lunsumio (mosunetuzumab) subcutaneous (SC)<\/strong> injection for adult patients with <strong>relapsed or refractory (R\/R) follicular lymphoma (FL)<\/strong> after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Lunsumio (mosunetuzumab) SC injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Roche<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EU)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Conditional marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>R\/R follicular lymphoma (FL) after \u22652 prior lines<\/td><\/tr><tr><td><strong>Study Basis<\/strong><\/td><td>Phase\u202fI\/II GO29781 (PK non\u2011inferiority, comparable safety)<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>SC administration reduces infusion time from ~4\u202fhours to &lt;10\u202fminutes<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Full approval contingent on confirmatory Phase\u202fIII data; US FDA sBLA filing planned for Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> First\u2011in\u2011class <strong>CD20\u00d7CD3 T\u2011cell engaging bispecific antibody<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Activates and redirects patient\u2019s existing T\u2011cells to release cytotoxic proteins toward CD20\u2011positive B\u2011cells, eliminating malignant B\u2011cells<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Subcutaneous injection offers <strong>improved patient convenience<\/strong> and <strong>reduced healthcare resource burden<\/strong> vs. IV<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Investigated as monotherapy and in combinations for B\u2011cell non\u2011Hodgkin lymphoma (FL, DLBCL), other hematologic malignancies, and autoimmune diseases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-go29781-study\">Clinical Evidence \u2013 GO29781 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Phase\u202fI\/II, open\u2011label, PK bridging study (SC vs. IV)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>PK non\u2011inferiority (AUC and Cmax)<\/td><\/tr><tr><td><strong>Key Finding<\/strong><\/td><td>SC met non\u2011inferiority criteria; safety profile consistent with IV, no unexpected signals<\/td><\/tr><tr><td><strong>Efficacy (IV historical)<\/strong><\/td><td>ORR ~80%, CR ~60% in heavily pretreated FL (consistent across formulations)<\/td><\/tr><tr><td><strong>Patient Experience<\/strong><\/td><td>SC reduces treatment center time by &gt;90%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FL Market:<\/strong> EU incidence of <strong>~25,000 new FL cases<\/strong> annually; R\/R population represents ~40% of patients.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Lunsumio SC enters a crowded field including <strong>Gilead\u2019s Yescarta<\/strong> (CAR\u2011T), <strong>Novartis\u2019s Kymriah<\/strong> (CAR\u2011T), and <strong>Epizyme\u2019s Tazverik<\/strong> (EZH2 inhibitor), but offers the <strong>only SC bispecific<\/strong> with demonstrated OS benefit.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Roche projects Lunsumio SC to generate <strong>\u20ac450\u2011550\u202fmillion<\/strong> in EU sales by 2028, capturing <strong>30\u201135%<\/strong> of the R\/R FL market based on convenience and comparable efficacy.<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> SC formulation extends Lunsumio\u2019s lifecycle and reinforces Roche\u2019s leadership in hematology; US approval could add <strong>$600\u2011750\u202fmillion<\/strong> peak sales.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Phase\u202fIII trials in <strong>first\u2011line FL<\/strong> and <strong>DLBCL<\/strong> are enrolling; autoimmune indications (e.g., rheumatoid arthritis) in early development could unlock <strong>$2\u202fbillion+<\/strong> additional peak sales potential.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Lunsumio SC\u2019s commercial performance, regulatory pathway, and pipeline expansion. Actual results may differ materially due to risks including confirmatory trial outcomes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48639,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,940,15,163,939],"class_list":["post-48637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-otcmkts-rhhby","tag-product-approvals","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48637\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48637\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T12:27:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T12:27:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma\",\"datePublished\":\"2025-11-19T12:27:57+00:00\",\"dateModified\":\"2025-11-19T12:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901-1.webp\",\"keywords\":[\"Cancer\",\"OTCMKTS: RHHBY\",\"Product approvals\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48637#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48637\",\"name\":\"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901-1.webp\",\"datePublished\":\"2025-11-19T12:27:57+00:00\",\"dateModified\":\"2025-11-19T12:27:58+00:00\",\"description\":\"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\\\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\\\/II data showing PK non\u2011inferiority to the IV formulation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48637\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48637#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48637","og_locale":"en_US","og_type":"article","og_title":"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma","og_description":"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.","og_url":"https:\/\/flcube.com\/?p=48637","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-19T12:27:57+00:00","article_modified_time":"2025-11-19T12:27:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48637#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48637"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma","datePublished":"2025-11-19T12:27:57+00:00","dateModified":"2025-11-19T12:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48637"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48637#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","keywords":["Cancer","OTCMKTS: RHHBY","Product approvals","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48637#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48637","url":"https:\/\/flcube.com\/?p=48637","name":"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48637#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48637#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","datePublished":"2025-11-19T12:27:57+00:00","dateModified":"2025-11-19T12:27:58+00:00","description":"Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted conditional marketing authorization for Lunsumio (mosunetuzumab) subcutaneous (SC) injection for adult patients with relapsed or refractory (R\/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on Phase\u202fI\/II data showing PK non\u2011inferiority to the IV formulation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48637#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48637"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48637#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","width":1080,"height":608,"caption":"Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48637#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48637"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48637\/revisions"}],"predecessor-version":[{"id":48640,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48637\/revisions\/48640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48639"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}